Difference between revisions of "Pamidronate (Aredia)"
Jump to navigation
Jump to search
m |
m |
||
| Line 13: | Line 13: | ||
==Also known as== | ==Also known as== | ||
| − | pamidronate disodium omega, Pamisol | + | *'''Generic name:''' pamidronate disodium omega |
| + | *'''Brand name:''' Aredia, Padium, Pamisol | ||
==References== | ==References== | ||
| Line 19: | Line 20: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Intravenous medications]] | ||
| + | |||
[[Category:Bisphosphonates]] | [[Category:Bisphosphonates]] | ||
[[Category:Drugs FDA approved in 1991]] | [[Category:Drugs FDA approved in 1991]] | ||
Revision as of 00:03, 30 November 2017
General information
Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption. Exact mechanism not understood, but is believed to also involve blocking dissolution of bone calcium phosphate (hydroxyapatite) crystals.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
History of changes in FDA indication
- 10/31/1991: Initial FDA approval
Also known as
- Generic name: pamidronate disodium omega
- Brand name: Aredia, Padium, Pamisol